Voyager Therapeutics, Inc. (NASDAQ:VYGR) saw a significant growth in short interest in the month of September. As of September 29th, there was short interest totalling 793,817 shares, a growth of 43.7% from the September 15th total of 552,347 shares. Currently, 6.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 430,372 shares, the days-to-cover ratio is presently 1.8 days.

Shares of Voyager Therapeutics (NASDAQ:VYGR) opened at 20.53 on Tuesday. The company has a 50-day moving average of $16.95 and a 200 day moving average of $11.51. Voyager Therapeutics has a 12 month low of $8.10 and a 12 month high of $25.99. The company’s market capitalization is $552.32 million.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $3.27 million. Analysts forecast that Voyager Therapeutics will post ($2.84) EPS for the current year.

A number of equities analysts have weighed in on VYGR shares. Stifel Nicolaus started coverage on shares of Voyager Therapeutics in a research note on Friday, July 28th. They set a “buy” rating and a $20.00 price target on the stock. ValuEngine raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. BidaskClub raised shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. Chardan Capital reissued a “hold” rating on shares of Voyager Therapeutics in a research note on Sunday, September 10th. Finally, Evercore ISI assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, August 16th. They set an “outperform” rating and a $12.00 price target for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $26.29.

In other news, insider Bernard Ravina sold 5,490 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total value of $54,900.00. Following the sale, the insider now directly owns 17,157 shares in the company, valued at $171,570. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 38,430 shares of company stock worth $544,992 over the last 90 days. 8.00% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Voyager Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after purchasing an additional 13,194 shares during the last quarter. DAFNA Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 187.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after purchasing an additional 133,488 shares during the last quarter. State Street Corp grew its holdings in shares of Voyager Therapeutics by 11.8% in the 2nd quarter. State Street Corp now owns 184,526 shares of the company’s stock worth $1,653,000 after purchasing an additional 19,471 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Voyager Therapeutics by 26.8% in the 2nd quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock worth $1,197,000 after purchasing an additional 28,222 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Voyager Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after purchasing an additional 19,450 shares during the last quarter. 40.70% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Short Interest in Voyager Therapeutics, Inc. (VYGR) Grows By 43.7%” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/short-interest-in-voyager-therapeutics-inc-vygr-grows-by-43-7/1635331.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.